Publicaciones en colaboración con investigadores/as de University Hospital Heidelberg (8)

2024

  1. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

2022

  1. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

2020

  1. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer

    Clinical and Translational Radiation Oncology, Vol. 23, pp. 91-99

  2. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer

    Radiotherapy and Oncology, Vol. 148, pp. 57-64

  3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530

2019

  1. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428

2016

  1. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525

  2. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

    International Journal of Gynecological Cancer, Vol. 26, Núm. 5, pp. 898-905